Study of new interactions of glitazone’s stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins

This publication has 47 references indexed in Scilit:

• Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones
  PPAR Research, 2016
• Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ
  Journal of Structural Biology, 2015
• The Roles of Peroxisome Proliferator-Activated Receptors in the Metabolic Syndrome
  2014
• The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
  Current Diabetes Reports, 2013
• Phytol/Phytanic Acid and Insulin Resistance: Potential Role of Phytanic Acid Proven by Docking Simulation and Modulation of Biochemical Alterations
  PLOS ONE, 2013
• The rosiglitazone decision process at FDA and EMA. What should we learn?
  International Journal of Risk & Safety in Medicine, 2012
• Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes
  Toxicology and Applied Pharmacology, 2009
• Investigation of racemisation of the enantiomers of glitazone drug compounds at different pH using chiral HPLC and chiral CE
  Journal of Pharmaceutical and Biomedical Analysis, 2008
• Selective modulation of promoter recruitment and transcriptional activity of PPARγ
  Biochemical and Biophysical Research Communications, 2007
• Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities
  European Journal of Medicinal Chemistry, 2007